| Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update |
VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providers Net revenues of $28.5 million reported for Q1 Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwinds Strategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026 Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J. |
globenewswire.com |
2025-05-01 11:00:00 |
Czytaj oryginał (ang.) |
| INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t. |
businesswire.com |
2025-02-25 14:54:00 |
Czytaj oryginał (ang.) |
| ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share in cash is fair to Intra-Cellular shareholders. Halper Sadeh encourages Intra-Cellular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation. |
businesswire.com |
2025-02-25 01:15:00 |
Czytaj oryginał (ang.) |
| ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales |
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales. |
zacks.com |
2025-02-24 14:25:21 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates |
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.30 per share a year ago. |
zacks.com |
2025-02-21 12:10:35 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results |
Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million , representing a 51% increase over the same period in 2023 |
globenewswire.com |
2025-02-21 10:00:00 |
Czytaj oryginał (ang.) |
| Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last? |
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says. |
cnbc.com |
2025-01-21 16:35:11 |
Czytaj oryginał (ang.) |
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders |
NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Enfusion, Inc. (NYSE: ENFN)'s sale to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock. If you are an Enfusion shareholder, click here to learn more about your rights and options. |
prnewswire.com |
2025-01-16 14:10:00 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer |
JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end. |
zacks.com |
2025-01-14 11:56:09 |
Czytaj oryginał (ang.) |
| Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last? |
Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-01-14 10:01:36 |
Czytaj oryginał (ang.) |
| INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular Therapies, Inc. (NasdaqGS: ITCI) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Intra-Cellular will receive $132.00 in cash for each share of Intra-Cellular that they own. KSF is seeking to determine whether this consideration and the process t. |
businesswire.com |
2025-01-13 20:38:00 |
Czytaj oryginał (ang.) |
| Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Intra-Cellular Therapies (Nasdaq: ITCI) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Intra-Cellular Therapies stockholders will receive only $132.00 per share in cash. |
businesswire.com |
2025-01-13 20:15:00 |
Czytaj oryginał (ang.) |
| BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal |
Intra-Cellular +32.49 (+34.25%) Johnson & Johnson +2.22 (+1.56%) |
https://thefly.com |
2025-01-13 16:23:32 |
Czytaj oryginał (ang.) |
| ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz |
Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040. |
zacks.com |
2025-01-13 14:41:30 |
Czytaj oryginał (ang.) |
| Drugmakers rush to sign deals on first day of industry conference |
Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco. |
reuters.com |
2025-01-13 14:07:32 |
Czytaj oryginał (ang.) |
| Intra-Cellular just downgraded at Morgan Stanley, here's why |
Intra-Cellular +32.2 (+33.94%) Johnson & Johnson +1.38 (+0.97%) |
https://thefly.com |
2025-01-13 11:58:32 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B |
Shares of Intra-Cellular Therapies (ITCI) are surging 35% in premarket trading Monday after Johnson & Johnson (JNJ) said it will acquire the biopharmaceutical company for roughly $14.6 billion. |
investopedia.com |
2025-01-13 11:25:48 |
Czytaj oryginał (ang.) |
| ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share in cash is fair to Intra-Cellular shareholders. Halper Sadeh encourages Intra-Cellular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation. |
businesswire.com |
2025-01-13 10:06:00 |
Czytaj oryginał (ang.) |
| Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains? |
Intra-Cellular (ITCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-01-13 08:56:20 |
Czytaj oryginał (ang.) |
| J&J to buy Intra-Cellular Therapies for $14.6 billion |
Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments. |
reuters.com |
2025-01-13 08:38:07 |
Czytaj oryginał (ang.) |
| Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. |
Acquisition includes CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults |
globenewswire.com |
2025-01-13 08:32:00 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting |
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder |
globenewswire.com |
2024-12-11 10:00:00 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move |
CAPLYTA showed strong revenue growth, with Q3 2024 net product revenues of $125.8 million, which was a 39% year-over-year increase. Potential revenue boost if CAPLYTA's label is expanded to include it as an adjunctive therapy for major depressive disorder, addressing a significant unmet need. Lenrispodun, a PDE inhibitor, is in a phase 2 study for Parkinson's Disease, with potential data release by late 2025/early 2026, offering another blockbuster opportunity. |
seekingalpha.com |
2024-12-09 00:34:50 |
Czytaj oryginał (ang.) |
| ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD |
Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants. |
zacks.com |
2024-12-04 15:00:47 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy |
BEDMINSTER, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced that it has recently submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for CAPLYTA (lumateperone) for the treatment of Major Depressive Disorder (MDD) in adults, as adjunctive therapy to antidepressants. |
globenewswire.com |
2024-12-03 09:30:00 |
Czytaj oryginał (ang.) |
| Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report? |
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-11-29 14:37:13 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences |
BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences: |
globenewswire.com |
2024-11-19 10:00:00 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress |
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) |
globenewswire.com |
2024-11-07 10:00:00 |
Czytaj oryginał (ang.) |
| Intra-Cellular's schizophrenia drug meets main goal in late-stage trial |
Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial. |
reuters.com |
2024-11-05 09:14:03 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript |
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman and CEO Mark Neumann - EVP and CCO Sanjeev Narula - CFO Suresh Durgam - EVP and CMO Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Charles Duncan - Cantor Jason Gerberry - Bank of America Securities Jeff Hung - Morgan Stanley Michael DiFiore - Evercore David Amsellem - Piper Sandler Joel Beatty - Baird Corinne Johnson - Goldman Sachs Operator Good day and thank you for standing by. Welcome to Intra-Cellular Therapies 3Q 2024 Earnings Conference Call. |
seekingalpha.com |
2024-10-30 15:34:06 |
Czytaj oryginał (ang.) |
| ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales |
Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales. |
zacks.com |
2024-10-30 14:06:10 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates |
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.25 per share a year ago. |
zacks.com |
2024-10-30 11:40:27 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance |
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase |
globenewswire.com |
2024-10-30 09:30:00 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy? |
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-23 15:07:53 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast |
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, October 30, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended September 30, 2024. |
globenewswire.com |
2024-10-17 12:00:00 |
Czytaj oryginał (ang.) |
| Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe |
ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning. |
zacks.com |
2024-10-11 15:30:28 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress |
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) |
globenewswire.com |
2024-09-23 12:00:00 |
Czytaj oryginał (ang.) |
| Why Is Intra-Cellular (ITCI) Down 2.7% Since Last Earnings Report? |
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-09-06 16:37:56 |
Czytaj oryginał (ang.) |
| Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences |
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences: |
globenewswire.com |
2024-08-28 12:00:00 |
Czytaj oryginał (ang.) |
| Biotech Stock Pulls Back After Earnings Report; Profits On The Horizon |
This biotech stock is in a base and seeking support at a moving average. The company's losses are dwindling and analysts see profits coming. |
investors.com |
2024-08-08 15:06:06 |
Czytaj oryginał (ang.) |
| Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat |
Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales. |
zacks.com |
2024-08-08 14:56:18 |
Czytaj oryginał (ang.) |